EUCTR2006-006532-21-FR
Active, not recruiting
Phase 1
Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer (PETACC-6) - PETACC-6
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- locally advanced rectal cancer
- Sponsor
- EORTC
- Enrollment
- 1090
- Status
- Active, not recruiting
- Last Updated
- 9 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Male or female patients with histologically proven adenocarcinoma of the rectum (tumour \= 12
- •cm from the anal verge as assessed by rigid proctoscopy).
- •¨ Clinical tumour stage T3/4 or any node\-positive disease (clinical stage according the TNM
- •classification system (Appendix J), positive nodes as diagnosed on endorectal ultrasound and/or
- •MRI). Tumour is staged by preferably a high resolution MRI. If MRI is not available,
- •locoregional staging must be performed by computed tomography plus endorectal ultrasound.
- •¨ No evidence of metastatic disease (as evidenced by negative CT\-scan of the chest and
- •¨ The disease must be considered either resectable at the time of entry or expected to become
- •resectable after preoperative chemoradiation.
- •¨ Age \= 18 years.
Exclusion Criteria
- •\-severe renal impairment (creatinine clearance below 30 ml/min)
- •\-pregnancy and lactation
- •\-hypersensitivity to capecitabine or 5\-FU or to any of the excipients
- •\-patients with history of severe and unexpected reactions to fluoro pyrimidine therapy
- •\-patients with known dihydropyrimidine dehydrogenase (DPD) deficiency
- •\-patients with severe leucopenia, neutropenia and thrombocytopenia
- •\-severe hepatic impairment
- •\-concomittant use of sorivudine or its chemically related analogues such as brivudine
- •\-patients with known allergy against oxaliplatin or other platinum compounds
- •\-patients with impaired bone marrow function
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
clinical study to evaluate the efficacy of a two drug combination versus a single drug therapy in the treatment of locally advanced rectal cancer.locally advanced rectal cancerMedDRA version: 17.0Level: PTClassification code 10038050Term: Rectal cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0Level: PTClassification code 10038049Term: Rectal cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2006-006532-21-DEEORTC1,094
Active, not recruiting
Not Applicable
Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancerRectal cancerLocally Advanced Rectal CancerCancer - Bowel - Back passage (rectum) or large bowel (colon)ACTRN12608000403336Australasian Gastro-Intestinal Trials Group (AGITG)1,090
Active, not recruiting
Phase 1
Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer (PETACC-6) - PETACC-6locally advanced rectal cancerMedDRA version: 9.1 Level: LLT Classification code 10038050 Term: Rectal cancer stage IIIMedDRA version: 9.1 Level: LLT Classification code 10038049 Term: Rectal cancer stage IIEUCTR2006-006532-21-GBEuropean Organization for Research and Treatment of Cancer1,094
Active, not recruiting
Phase 1
Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer (PETACC-6)locally advanced rectal cancerMedDRA version: 14.1Level: PTClassification code 10038050Term: Rectal cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10038049Term: Rectal cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2006-006532-21-BEEORTC1,090
Recruiting
Not Applicable
Effect of preoperative concurrent chemoradiotherapy in patients with adenocarcinoma of esophagusHealth Condition 1: null- patients with ECOG (0,1,2) - Good performance statusCTRI/2013/09/003981not applicable160